ArticleGeneral thoracic and cardiovascular surgery2026
Real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy.
Article in General thoracic and cardiovascular surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Methodological considerations in real-world outcomes of unresected non-small cell lung cancer following neoadjuvant chemoimmunotherapy.General thoracic and cardiovascular surgery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough neoadjuvant chemoimmunotherapy is promising for resectable stage II-III non-small cell lung cancer (NSCLC), some patients do not proceed to surgery. We aimed to investigate the clinical course and outcomes of patients whose surgery was cancelled after neoadjuvant chemoimmunotherapy.
methodsThis retrospective multicentre study (CReGYT-04: Neo-Venus study) included patients with resectable clinical stage II-III NSCLC who received nivolumab neoadjuvant chemotherapy (2023-2024). Clinical characteristics were compared between a surgery-cancelled group and surgery-performed group. In the surgery-cancelled group, the reasons for surgery cancellation, salvage treatments, and effects of immune-related adverse events (irAEs) were evaluated.
resultsAmong 126 patients, 11 (8.7%) did not undergo surgery. Compared with the surgery-performed group, the surgery-cancelled group had a heavier smoking history, a higher frequency of adjacent organ invasion, a greater proportion of squamous cell carcinoma histology, and more frequent Grade 3-4 irAEs. Reasons for cancelling surgery included disease progression (n = 6, 55%), patient refusal (n = 3, 27%), and irAEs (n = 2, 18%). Four (36%) patients received intensive salvage treatment (concurrent chemoradiotherapy, 3 patients; chemoimmunotherapy, 1 patient), whereas seven patients received best supportive care (n = 4) or less-intensive salvage treatment such as radiotherapy alone (n = 2) and docetaxel monotherapy (n = 1). Among the four patients in the surgery-cancelled group who developed Grade 3-4 irAEs, none received intensive salvage treatment.
conclusionsIntensive salvage treatment was administered to 36% of patients whose surgery was cancelled after neoadjuvant chemoimmunotherapy. These findings highlight the importance of optimising patient selection and irAE management to preserve opportunities for curative-intent treatment when adopting neoadjuvant strategies.
Indexed as
Identifiers
42455428What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.